Published online before print July 17, 2003, doi: 10.1161/01.ATV.0000087034.22709.5F
© 2003 American Heart Association, Inc.
Thrombosis |
Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation
From the Division of Cardiology, University of Naples, "Federico II"; Division of Cardiology, Seconda Università di Napoli (P.G.); and Stazione Zoologica "A. Dohrn" (A.R., M.D.F.), Naples, Italy.
Correspondence to Paolo Golino, MD, PhD, Division of Cardiology, Seconda Università di Napoli, Piazza Luigi Miraglia, 2, 80123 Naples, Italy. E-mail paolo.golino{at}unina2.it
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Tissue factor (TF) is normally expressed at low levels in the media of blood vessels, but it is readily induced after vessel injury. It is not known whether vascular damage per se or thrombus formation is responsible for this phenomenon.
Methods and Results— Cyclic flow variations (CFVs), attributable to recurrent thrombus formation, were induced in stenotic rabbit carotid arteries with endothelial injury. CFVs were observed for 30 minutes and 2, 4, and 8 hours in different groups of animals. Another group of rabbits pretreated with hirudin before inducing arterial damage to inhibit thrombus formation was observed for 8 hours. Arterial sections were immunostained for TF. Undamaged arteries served as controls. In additional rabbits, in situ hybridization experiments were performed. No TF expression was observed in the media of control vessels, whereas a progressive increase in TF mRNA and protein expression was observed in carotid arteries as CFVs progressed. No increase in TF expression was observed in animals pretreated with hirudin. In vitro experiments demonstrated that TF mRNA is induced in smooth muscle cells stimulated with activated platelets as well as with some platelet-derived mediators.
Conclusions— This phenomenon may contribute to sustain intravascular thrombus formation after the initial thrombogenic stimulus.
Key Words: tissue factor • intravascular thrombosis • platelets • platelet-derived mediators
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Tissue factor (TF), a transmembrane glycoprotein, plays a pivotal role in the activation of the coagulation cascade. TF binds circulating factor VII (FVII) with high affinity, resulting in formation of a complex that activates factors IX and X, ultimately leading to generation of thrombin and thrombus formation.1–3
Several studies indicate that TF-dependent activation of the coagulation cascade plays an important role in the pathophysiology of intravascular thrombus formation.3–10 Because the formation of the complex TF-FVII represents the initial event in the activation of the coagulation cascade, TF expression in the arterial wall is tightly regulated. For instance, endothelial cells, being in contact with circulating blood, normally do not express TF in significant amounts, whereas the activity of this protein increases significantly from the media to the adventitia.4,7,11–15 The end point of this tight regulation of TF expression in the vascular wall is the avoidance of unwanted intravascular activation of the coagulation, together with a prompt hemostasis in the event of loss of integrity of the vascular wall.
TF expression within the vascular wall is not steady but rather can be modulated by a variety of substances. Phorbol esters,16,17 interleukin 1,18 
-thrombin,19 endotoxin,17,20 tumor necrosis factor,21 and oxygen free radicals22 all induce TF expression, whereas prostacyclin and its analogues result in inhibition of TF expression.23,24 TF can also be rapidly induced in rat aortas after balloon angioplasty,25 but whether vessel injury per se or intravascular thrombus formation26 caused by the vascular injury that follows angioplasty is responsible for this induction is still unknown.
Therefore, the aims of the present study were to investigate (1) whether TF is upregulated in the arterial wall during ongoing thrombosis, (2) which cellular populations are involved in this phenomenon, and (3) whether activated platelets and some platelet-derived mediators are involved in this TF induction.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Rabbit Model of Thrombosis
The rabbit model of recurrent intravascular thrombus formation used in the present study has been described in detail elsewhere27,28 and represents a modification of the canine model originally described by Folts and colleagues.29,30 This experimental preparation is based on carotid arterial damage with a superimposed external stenosis resulting in cyclic flow variations (CFVs), a typical pattern of flow attributable to recurrent cycles of thrombus formation and dislodgement.27
Experimental Protocol
Immunohistochemical Experiments
Animals were divided into 2 groups. In the first group, CFVs were observed for 30 minutes (group Ia) and 2 (group Ib), 4 (group Ic), and 8 hours (group Id, n=6 in each group). The second group of animals was included to differentiate the effects of the injury per se from those of thrombus formation. It is known, in fact, that vascular injury may upregulate TF in rat aortas.25 Group II rabbits (n=6) were treated 10 minutes before performing the damage with a bolus of hirudin (1 mg/kg IV) to prevent CFVs. Arterial damage was performed, and an external stenosis was created exactly as described for the animals in group I; however, because of hirudin administration, CFVs did not develop in any of the 6 rabbits. Animals were followed for 8 hours and then euthanized. Contralateral carotid arteries, not subjected to damage and, therefore, not developing CFVs, served as negative controls. For additional information, please see the online supplement at http://atvb.ahajournals.org.
In Situ Hybridization
To verify whether TF induction evidenced by immunohistochemistry was the consequence of exposure of preformed, encrypted TF31,32 or required TF gene transcription and de novo protein synthesis, in situ mRNA hybridization experiments were performed in additional groups of animals. For these experiments, animals were divided into 2 groups. In the first group, CFVs were observed for 30 minutes (group IIIa) and 2 (group IIIb), 4 (group IIIc), and 8 hours (group IIId, n=4 for each group). Group IV animals (n=4) included rabbits with arterial damage and external stenosis pretreated with hirudin, as previously described. For additional information, please see the online supplement.
TF Activity
To verify whether TF induction evidenced by immunohistochemistry was accompanied by TF protein expression, TF procoagulant activity was measured in arterial sections obtained from animals with CFVs. Also in this case, animals were divided into 2 groups. In the first group, CFVs were observed for 30 minutes (group Va) and 2 (group Vb), 4 (group Vc), and 8 hours (group Vd, n=4 for each group). Group VI animals (n=4) included rabbits with arterial damage and external stenosis pretreated with hirudin, as previously described. For additional information, please see http://atvb.ahajournals.org.
Detection of Cellular Populations Responsible for TF Expression
To characterize the cellular populations involved in TF upregulation, serial adjacent sections of carotid arteries from animals in group Id (8 hours of CFVs) were subjected to immunohistochemical staining specific for neutrophils using an antibody anti-CD 15 (Dako, Glostrup, Denmark), monocytes using an antibody anti-CD 68 (Dako), and smooth muscle cells (SMCs) using an anti-SMC -actin antibody (Sigma Chemicals, St Louis, Mo).
Activated Platelets and TF Protein and mRNA Expression in SMCs In Vitro
To test the hypothesis that platelet-derived mediators are responsible for thrombus-induced TF expression in SMCs, additional in vitro experiments were performed. Rabbit aorta SMCs were harvested and cultivated as previously described.33 For additional information, please see the online supplement.
Statistical Analysis
Data are expressed as mean±SD. A one-way ANOVA was used for multiple comparisons among groups. If an F value was significant, differences for individual groups were tested with Student’s t test for unpaired observations with Bonferroni’s correction. P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline TF Expression
Consistent with previous studies,4,25 no significant TF expression was observed in the media and in the intima of control, undamaged vessels, whereas a slight positivity was found only in focal spots in the adventitia (Figure 1A). No monocytes or neutrophils were detected in control vessels, whereas an intense positivity for
-actin was observed in the media, as expected (data not shown).
|
Time Course of TF Expression During CFVs
Figure 1 illustrates immunohistochemical staining for TF in arterial sections obtained from animals subjected to different time periods of CFVs. After 30 minutes of CFVs, a slight positivity for TF was observed in the media (Figure 1B), averaging 0.47±0.44 of the semiquantitative score (Figure 2), although this increase did not reach statistical significance. TF expression increased progressively to 1.3±0.45, 1.8±0.55, and 2.3±0.60 at 2, 4, and 8 hours, respectively (Figure 2). At 8 hours, the media was intensively and diffusely positive for TF, indicating that intravascular thrombus formation is associated with a significant TF upregulation in the arterial wall (Figures 1C through 1E). Interestingly, arterial sections obtained from animals pretreated with hirudin, subjected to the same degree of vascular damage but not developing CFVs, showed only a slight positivity for TF (Figure 1F) that was not statistically different from that observed in control, undamaged vessels (Figure 2). These data strongly suggest that thrombus formation plays a prominent role in inducing TF upregulation in the arterial wall rather than the damage of the vessel.
|
Characterization of the Cellular Population Expressing TF
To determine the cellular population responsible for the observed expression of TF during recurrent thrombosis, adjacent sections were stained for TF and either neutrophils, monocytes, or SMCs. These sections revealed that TF colocalized mostly with SMCs, indicating that SMCs were predominantly responsible for TF upregulation, although at later time points, ie, 8 hours, some degree of TF-expressing cells infiltrating the arterial wall could be observed, particularly in the luminal side of the vessels (Figure 3).
|
In Situ Hybridization
To determine whether TF protein expression was accompanied by de novo TF mRNA transcription, in situ hybridization experiments were performed. These experiments showed a pattern of TF mRNA expression similar to that of TF protein expression evidenced by immunohistochemistry. In particular, in arterial sections incubated with the antisense probe, a progressive increase in TF mRNA expression was observed, starting at 30 minutes of CFVs and peaking at 8 hours (Figure 4). Minimal amounts of TF mRNA, again mainly localized in the adventitia, were detected in undamaged vessels; no detectable signal was observed with the sense probe (negative controls). Carotid arteries obtained from animals pretreated with hirudin showed minimal induction of TF mRNA (Figure 4), indicating that the positivity for TF mRNA was specific.
|
TF Activity in Carotid Arteries With and Without CFVs
TF procoagulant activity increased significantly in the media isolated from vessels with CFVs compared with the media obtained from control arteries, starting at 2 hours and peaking at 8 hours. Data are summarized in online Table I, available at http://atvb.ahajournals.org.
Activated Platelets and TF mRNA and Protein Expression in SMCs In Vitro
TF m-RNA was barely detectable in quiescent SMCs. Stimulation with collagen-activated platelets caused a time-dependent increase in TF mRNA levels compared with unstimulated SMCs, peaking at 2 hours. TF mRNA levels progressively decreased thereafter, returning to baseline values at 24 hours. SMCs stimulated with collagen alone (Figure 5) or with nonactivated platelets (data not shown) did not show any increase in TF mRNA expression. TF protein, evaluated as procoagulant activity, showed a similar pattern of expression, although with a time shift of approximately 2 hours (Figure 5).
|
TF Expression in SMCs Stimulated With Platelet-Derived Mediators
To determine the relative contribution of different platelet-derived mediators on TF expression in SMCs, TF procoagulant activity was measured at different time points after stimulation with increasing concentrations of ADP, U46619, 5-HT, PAF, platelet-derived growth factor, and TRAP. All agonists except ADP induced a time- and dose-dependent increase in TF expression, the most potent being platelet-derived growth factor and TRAP. Of note is the observation of a synergistic effect when all agonists were added together at subthreshold concentration (online Table 2, available at http://atvb.ahajournals.org).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The main findings of the present study are as follows: (1) TF mRNA, protein, and procoagulant activity are readily upregulated in the arterial wall during ongoing recurrent thrombus formation; (2) a prominent role for this TF upregulation is played by thrombin generated during thrombus formation rather than by the arterial damage per se; (3) TF is predominantly upregulated in arterial smooth muscle cells, with very little contribution of infiltration of the arterial wall by TF-expressing cells, such as monocytes and neutrophils; and (4) platelets and soluble platelet-derived chemical mediators induce TF mRNA in SMCs in vitro, suggesting their important role in inducing TF in the arterial wall in vivo.
TF is the main initiator of the extrinsic coagulation pathway. The tight binding between TF and FVII, leading to the formation of a complex able to activate factors IX and X, is the first step of this pathway.1–4 As a consequence, TF expression in the arterial wall is finely regulated. TF is normally sequestered from circulating blood, because endothelial cells do not express this protein in significant amounts,4 whereas its activity increases from the media to the adventitia.7,11–15 Therefore, when an atherosclerotic plaque ruptures, preformed TF present in the subendothelium is suddenly exposed to flowing blood, contributing to formation of a thrombus and to the sudden onset of acute coronary syndromes.5–9
Apart from the preformed protein, induction of TF in the arterial wall might also represent an important mechanism regulating thrombus formation. In fact, TF can be induced by a variety of stimuli, including endotoxin,17,20 phorbol esters,16,17 interleukin-1,18 -thrombin,19 tumor necrosis factor,21 and oxygen free radicals.22 Interestingly, previously published studies have already described induction of TF in the arterial wall after vessel injury using immunohistochemistry and either in situ hybridization or RNA blot analysis.25,34–36 Furthermore, a recent study showed not only that TF is rapidly induced in rabbit aortas after balloon injury but also that TF activity in the developing neointima is maintained at high levels for at least 8 weeks after the injury.37 However, data from those studies do not allow one to dissect out the relative contribution of the injury per se from that of thrombus formation, because mural thrombi almost invariably form after balloon injury. The present study was designed to clarify this issue, and our data indeed demonstrate that TF in the arterial wall is primarily induced as a consequence of platelet activation, thrombin generation, and thrombus formation rather than vessel injury per se.
The observation that damaged vessels obtained from animals pretreated with hirudin, in which CFVs could not be induced, did not show a significant increase in TF compared with vessels obtained from animals with CFVs obviously points toward a prominent role of thrombin in this phenomenon. However, it should be outlined that it is likely that other platelet-derived chemical mediators also play a role in vivo. This is suggested by 2 lines of evidence. First, pretreatement with hirudin not only eliminated the effects of thrombin but also those of other mediators, because CFVs did not develop. Second, direct stimulation of SMCs in vitro with platelet-derived mediators showed that most of them (with the possible exception of ADP) are able to induce TF. Thus, although probably thrombin occupies a central role in TF induction after arterial damage, an important contribution of other mediators is likely to occur.
The demonstration that intravascular thrombus induces TF expression in the media may be particularly relevant to the pathophysiology of acute coronary syndromes as well as of percutaneous interventions. Induction of TF on the surface of SMCs exposed to flowing blood could not only provide a site for additional activation of the coagulation cascade but could also participate in the development of neointimal hyperplasia, as recent preliminary data from our laboratory seem to suggest.38 It should be emphasized, however, that the results obtained in the experimental model used in the present study might be specific for this model and that it remains to be determined whether the same findings can be observed in models characterized by a more severe vascular injury, such as balloon-induced injury.
Candidates for the observed thrombus-induced TF upregulation are activated platelets and platelet-derived mediators. Data from the present study indicate that soluble mediators secreted from activated platelets rapidly induce TF mRNA and protein in SMCs in culture. In vivo, however, the potential role of other cell types, such as leukocytes, or mediators, such as thrombin, cannot be ruled out.
The gene coding for TF belongs to the so-called immediate early genes, a group of sentinel genes that are able to answer immediately to different noxious stimuli by promoting the transcription of sequences encoding for proteins that explicate a protective effect.39 In this respect, the data from the present study suggest the existence of a new pathophysiological mechanism initially triggered by intravascular thrombus formation. After the initial thrombogenic stimulus, activated platelets and perhaps other components of the thrombus stimulate SMCs in the arterial wall to synthesize new TF, which may help sustain the thrombotic process and activate cell proliferation38 and perhaps gene expression. In this pathophysiological scheme, TF may represent a link between thrombosis, inflammation, and atherosclerosis.
In conclusion, the present study suggests the existence of a positive feedback loop for expression of TF in the arterial wall. Preformed TF is important in initiating intraarterial thrombus formation, which, in turn, is able to stimulate the synthesis of new TF, thus sustaining the thrombotic process and perhaps SMC proliferation.
|
Acknowledgments |
|---|
This study was supported in part by a grant from Regione Campania (L. n. 41/99).
|
Footnotes |
|---|
*These authors contributed equally to this study.
Received May 27, 2003; accepted July 8, 2003.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Nemerson Y. Tissue factor and haemostasis. Blood. 1988; 71: 1–8.
2. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A. 1977; 74: 5260–5264.
3. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Atherioscler Thromb. 1992; 12: 1111–1121.
4. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989; 86: 2839–2843.
5. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaque: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow condition. Circulation. 1999; 99: 1780–1787.
6. Toschi V, Gallo R, Lettino R, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997; 95: 594–599.
7. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK, Ezekowitz MD. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res. 1994; 74: 56–63.
8. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens form patients with stable and unstable coronary syndromes. Circulation. 1995; 91: 619–622.
9. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997; 349: 769–771.[CrossRef][Medline] [Order article via Infotrieve]
10. Ragni M, Golino P, Cirillo P, Scognamiglio A, Piro O, Esposito N, Battaglia C, Botticella F, Ponticelli P, Ramunno L, Chiariello M. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation. 2000; 102: 113–117.
11. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissue. Am J Pathol. 1989; 143: 1087–1097.
12. Fleck RA, Mohan Rao V, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res. 1990; 57: 765–781.[CrossRef]
13. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest. 1996; 75: 451–461.[Medline] [Order article via Infotrieve]
14. Taubman MB. Tissue factor regulation in vascular smooth muscle: a summary of studies performed using in vivo and in vitro models. Am J Cardiol. 1993; 72: 55C–61C[CrossRef][Medline] [Order article via Infotrieve]
15. Moreno PR, Bernardi VH, Lopez-Cuellar J, Newell JB, McMellon C, Gold HK, Palacios IF, Fuster V, Fallon JT. Macrophages, smooth muscle cells and tissue factor in unstable angina. Circulation. 1996; 94: 3090–3097.
16. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. J Biol Chem. 1989; 264: 20705–20713.
17. Crossman DC, Carr DP, Tuddenham EGD, Pearson JD, McVey JH. The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol esters. J Biol Chem. 1990; 265: 9782–9787.
18. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci S A. 1986; 83: 3460–3464.
19. Brox JH, Østerud B, Bjorklid E, Fenton JW 2nd. Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets. Br J Haematol. 1984; 57: 239–246.[Medline] [Order article via Infotrieve]
20. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987; 79: 124–130.
21. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res. 1989; 53: 231–241.[CrossRef][Medline] [Order article via Infotrieve]
22. Golino P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N, Scognamiglio A, Trimarco B, Iaccarino G, Condorelli M, Chiariello M, Ambrosio G. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med. 1996; 2: 35–40.[CrossRef][Medline] [Order article via Infotrieve]
23. Crutchley DJ, Solomon DE, Conanan LB. Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism. Atheroscler Thromb. 1992; 12: 664–670.
24. Crutchley DJ, Conanan LB, Toledo AW, Solomon DE, Que G. Effects of prostacyclin analogues on human endothelial cell tissue factor expression. Arterioscler Thromb. 1993; 13: 1082–1089.
25. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest. 1993; 91: 2253–2259.
26. Kaikita K, Ogawa H, Yasue H, Takeya M, Takahashi K, Saito T, Hayasaki K, Horiuchi K, Takizawa A, Kamikubo Y, Nakamura S. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Atheroscler Thromb Vasc Biol. 1997; 17: 2232–2237.
27. Golino P, Ambrosio G, Pascucci I, Ragni M, Russolillo E, Chiariello M. Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation. Thromb Haemost. 1992; 67: 302–305.[Medline] [Order article via Infotrieve]
28. Golino P, Cappelli Bigazzi M, Ambrosio G, Ragni M, Russolillo E, Condorelli M, Chiariello M. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ Res. 1992; 71: 1447–1453.
29. Folts JD, Crowell EB Jr, Rowe CG. Platelet aggregation in partially obstructed vessels and its elimination by aspirin. Circulation. 1976; 54: 365–370.
30. Folts J. An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation. 1991; 83 (suppl 4): IV3–IV14.
31. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci U S A. 1990; 87: 6995–6999.
32. Bevers EM, Comfurius P, Dekkers DW, Harmsma M, Zwaal RF. Transmembrane phospholipid distribution in blood cells: control mechanisms and pathophysiological significance. J Biol Chem. 1998; 379: 973–986.
33. Cirillo P, Golino P, Ragni M, Battaglia C, Pacifico F, Formisano S, Buono C, Condorelli M, Chiariello M. Activated platelets and leucocytes cooperatively stimulate SMC proliferation and proto-oncogene expression via release of soluble grow factors. Cardiovasc Res. 1999; 43: 210–217.
34. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendshein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation. 1995; 92: 3323–3330.
35. Speidel CM, Thornton JD, Meng YY, Eisenberg PR, Edgington TS, Abendschein DR. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa. Coron Artery Dis. 1996; 7: 57–62.[Medline] [Order article via Infotrieve]
36. Gallo R, Fallon JT, Toschi V, Gertz SD, Padurean A, Nemerson Y, Chesebro J, Fuster V, Badimon JJ. Bi-phasic increase of tissue factor activity after angioplasty in porcine coronary arteries. Circulation. 1995; 92: I-354. Abstract.
37. Hatakeyama K, Asada Y, Marutsuka K, Katahoka H, Sato Y, Sumiyoshi A. Expression of tissue factor in the rabbit aorta after balloon injury. Atherosclerosis. 1998; 139: 265–271.[CrossRef][Medline] [Order article via Infotrieve]
38. Cirillo P, Guarino A, Ragni M, Ezban M, Borrelli A, Calabro P, Manganiello V, Golino P. Activated coagulation factor FVII promotes smooth muscle cells proliferation in vitro. Circulation. 1999; 100: I699. Abstract.
39. Hartzell S, Ryder K, Lanahan A, Lan LF, Nathan D. A growth-factor responsive gene of murine BALB/c 3T3 cells encodes a protein homologous to human tissue factor. Mol Cell Biol. 1993; 9: 2567–2573.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||